Caladrius snags heart disease stem cell therapy from Shire – FierceBiotech
FierceBiotech |
Caladrius snags heart disease stem cell therapy from Shire
FierceBiotech Caladrius Biosciences picked up the worldwide rights to Shire's late-stage CD34+ stem cell therapy for refractory angina, while the big pharma will receive an undisclosed upfront fee, milestones and a royalty on product sales. The New Jersey-based … |
